OPPORTUNITY IN ORASURE STOCK FROM RAPID IN-HOME CORONAVIRUS TEST $OSUR
This post was just published on ZYX Buy Change Alert.
OraSure (OSUR) is developing a rapid in-home coronavirus test. Previously it received a $710,310 contract from the Biomedical Advanced Research and Development Authority which is part of the Department of Health and Human Services to develop a rapid in-home coronavirus test. This was a very small contract. However looking forward, if this test is quickly approved by the FDA, imagine the volume they could generate just from consumers buying it.
OraSure stock was purchased at an average price of $10.56. The first target zone was $13.73 to $16.14. Targets and stop zones are typically given in advance at the same time as the buy signal is given. … Please click here or the title below to read more.